Functional Brands Seeks Shareholder Approval for Reverse Stock Split to Avoid Delisting and Authorizes New Equity Plan
summarizeSummary
Functional Brands Inc. is holding a special meeting to vote on a reverse stock split to regain Nasdaq compliance and a new equity incentive plan that could significantly dilute shareholders.
check_boxKey Events
-
Reverse Stock Split Proposal
Shareholders will vote on a reverse stock split with a ratio ranging from 1-for-2 to 1-for-250. This action is proposed to increase the per-share market price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting by June 29, 2026.
-
New Equity Incentive Plan
The company seeks approval for the 2026 Equity Incentive Plan, which would authorize the issuance of 4,000,000 shares of common stock. The plan also includes an evergreen provision for annual increases of up to 5% of outstanding shares, representing significant potential dilution to current shareholders.
-
Delisting Threat and Financial Distress
The proposals are presented in the context of a Nasdaq delisting notice received on December 30, 2025, and the company's previously disclosed 'going concern' warning and material weaknesses in internal controls. Delisting would severely limit capital-raising ability and could lead to a total loss for investors.
-
Special Shareholder Meeting Scheduled
A special meeting of stockholders is scheduled for May 28, 2026, to vote on these critical proposals, along with an adjournment proposal if necessary to solicit additional proxies.
auto_awesomeAnalysis
This DEF 14A outlines critical proposals for Functional Brands Inc., a company already facing a "going concern" warning and Nasdaq delisting risk. The proposed reverse stock split (ranging from 1:2 to 1:250) is a direct response to the Nasdaq minimum bid price requirement, with a compliance deadline of June 29, 2026. Failure to approve this could lead to delisting, severely impacting the company's ability to raise capital and potentially resulting in a total loss for investors. Concurrently, the company seeks approval for a new 2026 Equity Incentive Plan, authorizing 4,000,000 new shares plus an annual evergreen provision of up to 5% of outstanding shares. This plan, while intended to attract and retain talent, represents substantial potential dilution (initially over 18%) for existing shareholders, especially given the company's precarious financial state and micro-cap valuation. The combination of these proposals highlights the company's urgent need to address its listing status and incentivize personnel amidst significant financial challenges.
At the time of this filing, MEHA was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.10 to $8.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.